证券记录 · 已归档季度
CLDX
Celldex Therapeutics, Inc. · Healthcare · Biotechnology
11被追踪持有人
-1Δ持有人
21.24M持有股份
$385.48M报告持仓市值
+0新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 -8.3% ·
股份流向 -2.5% ·
净新建仓位 -9.1%
— 公式
广泛派发 — 持股数量下降且持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +8 | 50.70M | $1.89B | +11 | −3 |
| Q1 2026 | 82 | +10 | 42.54M | $1.35B | +12 | −2 |
| Q4 2025 | 72 | 0 | 42.78M | $1.16B | — | — |
| Q3 2025 | 17 | 0 | 35.45M | $917.00M | — | — |
| Q2 2025 | 14 | 0 | 33.46M | $680.97M | — | — |
| Q1 2025 | 11 | -1 | 21.24M | $385.48M | — | −1 |
| Q4 2024 | 12 | +1 | 21.78M | $550.46M | +2 | −1 |
| Q3 2024 | 10 | -1 | 17.69M | $601.30M | — | −1 |
| Q2 2024 | 11 | — | 17.48M | $646.94M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 8.35M | -6.9% | $151.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 3.41M | -4.1% | $61.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 3.41M | -4.1% | $61.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | State Street Global Advisors ✦ (被动) | 2.81M | -13.2% | $50.94M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 2.62M | +4.2% | $47.57M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 12 | Geode Capital Management ✦ (被动) | 1.59M | +3.6% | $28.86M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Geode Capital Management ✦ (被动) | 1.59M | +3.6% | $28.86M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 871.63K | +92.6% | $15.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 603.40K | -14.8% | $10.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 603.40K | -14.8% | $10.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 406.16K | -21.6% | $7.37M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 406.16K | -21.6% | $7.37M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Millennium Management ✦ | 399.93K | +327.3% | $7.26M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 146.59K | +7.3% | $2.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 28.66K | -13.2% | $520,106 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| AQR Capital Management | $548,965 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 227 持有人, 72.32M 股份, $2.21B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据